Roche signs Hansoh Pharma oncology ADC collaboration with more than $15 billion in potential milestones
Roche and Hansoh Pharma have signed a major oncology licensing agreement involving antibody-drug conjugates, with more than $15 billion in potential milestone payments.
The collaboration covers a portfolio of ADC programmes targeting multiple cancers, including two existing programmes and potential additional projects, with Roche responsible for later-stage development and commercialisation outside Greater China.
Hansoh is eligible for $400 million upfront, $110 million on the first anniversary, more than $15 billion in contingent milestones and royalties, making the agreement one of the largest potential oncology licensing arrangements announced in 2026.
Field | Content |
Article Type | Deals |
Companies | Roche; Hansoh Pharma |
Deal Type | Strategic collaboration and licensing agreement |
Therapeutic Area | Oncology |
Therapeutic Modality | Antibody-drug conjugates (ADCs) |
Portfolio Scope | Two existing ADC programmes and potential additional projects |
Upfront Payment | $400 million |
First Anniversary Payment | $110 million |
Potential Milestones | More than $15 billion in contingent milestone payments |
Royalties | Additional royalties; rates not disclosed in supplied summary |
Total Potential Consideration | More than $15.51 billion including upfront and first-anniversary payments; contingent milestones are not guaranteed |
Licensed Territory | Outside mainland China, Hong Kong, Macau and Taiwan |
Roche Responsibilities | Later-stage development and commercialisation in licensed territories |
Hansoh Responsibilities | Collaboration on ADC programmes; detailed development responsibilities not confirmed in supplied summary |
Development Stage | Individual programme stages not specified in supplied summary |
What Happened | Roche and Hansoh Pharma entered a new oncology collaboration and licensing agreement covering a portfolio of antibody-drug conjugates. |
Why It Matters | The partnership substantially expands Roche's access to investigational ADC programmes and strengthens its oncology development pipeline. |
Strategic Rationale | Roche gains rights to multiple oncology assets while Hansoh receives substantial upfront funding and opportunities for future milestones and royalties. |
Previous Collaboration | This agreement is distinct from the companies' earlier ADC collaboration. |
Key Takeaway | The agreement provides Hansoh with $400 million upfront and potentially more than $15 billion in milestones; most of the headline value is contingent. |
What to Watch | Programme disclosures, clinical development progress, milestone achievements and regulatory submissions. |
Primary Source | Hansoh Pharma |
Primary Source URL | https://www.hspharm.com/news/news-detail-513518.htm |
Relevant Date | 19 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comments